Reunion's High-Stakes Pitch for Psychedelic Mental Health Drugs

MORRISTOWN, NJ – February 19, 2026 – Reunion Neuroscience, a biopharmaceutical company at the forefront of developing psychedelic-inspired medicines, is embarking on a whirlwind tour of five major investor conferences over the next three weeks. The move signals a concerted effort to secure the substantial capital required to push its novel mental health treatments through late-stage clinical trials and toward a market desperate for new options.

The company announced it will present and hold one-on-one meetings at a series of high-profile healthcare conferences, beginning with the virtual Oppenheimer conference on February 26th and culminating in a trio of events in Miami, including the Barclays Global Healthcare Conference in mid-March. For a privately held, clinical-stage company, this intensive investor outreach is a critical step in financing the future of its innovative drug pipeline.

Courting Capital for a New Era of Psychiatry

Reunion's agenda is packed, with scheduled presentations and meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 46th Annual Healthcare Conference in Boston, and a Miami blitz that includes the Leerink Partners, Citizens Life Sciences, and Barclays Global Healthcare conferences. This strategic roadshow is about more than just a press release; it's a direct appeal to the financial community that will decide the fate of its promising drug candidates.

For companies like Reunion, these conferences are vital platforms to gain visibility, validate their scientific progress, and attract the funding necessary to navigate the long and expensive path of drug development. The one-on-one meetings with investors are particularly crucial, offering management a chance to make a detailed case for their science and business strategy, away from the volatility of public market sentiment. This tour is a clear indication that the company is preparing for its next major phase of growth, which will require significant financial resources to fund larger, more complex clinical trials.

A Pipeline Aimed at Widespread Distress

At the heart of Reunion's pitch is its lead asset, RE104, a proprietary, next-generation psychedelic-inspired compound. The drug is a prodrug of 4-OH-DiPT, designed to target the serotonin 2A receptor, a key pathway for the therapeutic effects of psychedelics. What sets RE104 apart, and what the company highlights as a key advantage, is its short duration. The compound is engineered to provide a psychedelic experience lasting just three to four hours. This is a significant reduction from the six to eight hours often required for first-generation psychedelics like psilocybin, potentially making the treatment more practical for both patients and clinics.

The company is targeting conditions with profound unmet needs. Its RECONNECT Phase II study for postpartum depression (PPD) has already yielded promising results, meeting its primary endpoint with clinically meaningful improvements in depression scores. With only two FDA-approved drugs for PPD—one of which requires a lengthy intravenous infusion in a hospital setting—the market is ripe for a more convenient and effective single-dose treatment. Reunion plans to advance RE104 into a further Phase II trial for PPD later this year.

Beyond PPD, Reunion is tackling other significant mental health challenges. Its REKINDLE Phase II trial is currently investigating RE104 for adjustment disorder in patients with cancer and other medical illnesses—a condition for which the FDA has approved no specific treatments. Furthermore, a Phase II study named RECLAIM is set to begin in the first quarter of 2026 to evaluate RE104's potential in treating generalized anxiety disorder (GAD), a condition affecting nearly 7 million U.S. adults, half of whom find little relief from existing therapies. The company is also advancing a non-psychedelic candidate, RE245, with plans to file an Investigational New Drug (IND) application in 2026, demonstrating a diversified approach to neuropsychiatric drug development.

From Public Markets to Private Power

Reunion's current fundraising push follows a significant strategic pivot. After a period as a publicly traded entity, the company was taken private in June 2023 by MPM BioImpact in a deal valued at approximately $13.1 million. The move was designed to streamline operations and insulate the company's long-term research goals from the quarter-to-quarter pressures and administrative costs of the public markets, a common struggle for clinical-stage biotechs.

This strategy has proven remarkably successful. In May 2024, Reunion closed a $103 million Series A financing round, one of the largest for a private psychedelic biotech. Following the positive data from its PPD trial, the company's investors doubled down, expanding the Series A to a total of $133 million by September 2025. This massive infusion of capital from a syndicate of top-tier life science investors, including co-leaders MPM BioImpact and Novo Holdings, provided a powerful endorsement of Reunion's platform and clinical progress.

The funds are being used to advance the current clinical trials, but the high cost of late-stage drug development means the search for capital is continuous. This conference tour is the next logical step, building on proven momentum to fuel the journey toward potential regulatory submission and commercialization.

Mainstreaming Mind Medicine in a Crowded Field

Reunion's investor roadshow is taking place against the backdrop of a booming, and increasingly competitive, psychedelic medicine sector. Competitors like Lykos Therapeutics and Cybin have recently secured nine-figure financing rounds, underscoring the immense investor interest and the high cost of entry. In this crowded field, Reunion's differentiated asset—the short-acting RE104—is its key to standing out.

More broadly, the company's presence at mainstream Wall Street healthcare conferences signifies a larger shift. Psychedelic-inspired therapies, once on the fringes of medicine, are now being discussed and evaluated in the same boardrooms as traditional pharmaceuticals. This legitimization is crucial as companies navigate the complex regulatory landscape. With FDA guidance acknowledging the therapeutic potential of these compounds under supervised medical use, Reunion's leadership has expressed optimism for a potential approval as early as 2028. This long-term vision is precisely what the management team will be selling to investors in Boston and Miami, hoping to secure the partnerships and capital needed to turn a revolutionary scientific concept into a tangible medical reality.